Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer

Drugs

Volumn 71, Issue 5, 2011, Pages 541-555

  Bystricky, Branislav ^a   Okines, Alicia F C ^a   Cunningham, David ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; Bleomycin; Capecitabine; Cisplatin; Epirubicin; Etoposide; Fluorouracil; Folinic acid; Gastric cancer; Oesophageal cancer; Paclitaxel; Radiotherapy; Squamous cell cancer; Surgery; Vinblastine; Vindesine

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; VINBLASTINE;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; EARLY CANCER; ESOPHAGUS CANCER; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; PEROPERATIVE CARE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; STOMACH CANCER; SURGICAL MORTALITY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT;

EID: 79953172965     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585460-000000000-00000     Document Type: Article

References (73)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC CancerBase no. 10. Lyon, France: International Agency for Research on Cancer; 2010 [online]. Available from URL: http://globo can.iarc.fr [Accessed 2010 Nov 3].
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. Epub 2010 Jun 17.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regionsofthe world.JClin Oncol 2006;24(14): 2137-50. (Pubitemid 46655601)
4. CancerResearchUK. Oesophageal cancer - UK mortality statistics, 2010 [online]. Available from URL: http://info. cancerresearchuk.org/cancerstats/ types/oesophagus/survi val/ [Accessed 2010 Nov 3].
5. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85 (11): 1457-9. (Pubitemid 28502569)
6. Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell, 2009.
7. Altekruse S, Kosary CL, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2007. Bethesda (MD): National Cancer Institute. Based on November 2009 SEER data submission, posted to the SEER web site, 2010 [online]. Available from ULR: http://seer.cancer.gov/csr/ 1975-2007/ [Accessed 2010 Nov 3].
8. Ajani J. NCCN practice guidelines in oncology - esophageal cancer v2. 2010 [online]. Available from URL: http://www. nccn.org/professionals/physician- gls/pdf/esophageal.pdf [Accessed 2011 Jan 31].
9. Lerut T, Coosemans W, De Leyn P, et al. Is there a role for radical esophagectomy? Eur J Cardiothoracic Surg 1999; 16 Suppl. 1: S44-7.
10. Allum WH, Griffin SM, Watson A, et al.; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; British Society of Gastroenterology; British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50 Suppl. 5: v1-23.
11. Mariette C, Seitz JF, Maillard E, et al. Impact of neoadju- vant chemoradiation in localized esophageal cancer: results of a randomized, controlled phase III trial. FFCD 9901 [abstract no. 800O]. 35th ESMO Congress; 2010 Oct 8-12; Milan.
12. Chiu PW, Chan AC, Leung SF, et al. Multicenter prospec- tive randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous eso-phageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gas-trointest Surg 2005; 9 (6): 794-802. (Pubitemid 40883974)
13. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfrac-tionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15 (6): 947-54. (Pubitemid 39004352)
14. Herskovic A, Martz K, al-Sarraf M, et al. Combined che- motherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326 (24): 1593-8.
15. Cooper JS, Guo MD, Herskovic A, et al. Chemoradio- therapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281 (17): 1623-7. (Pubitemid 29211772)
16. Wong R, Malthaner R. Combined chemotherapy and radio- therapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; (1): CD002092.
17. Sykes AJ, Burt PA, Slevin NJ, et al. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 1998; 48 (1): 15-21. (Pubitemid 28391963)
18. Amdal CD, Jacobsen AB, Tausjø JE, et al. Radical treat- ment for oesophageal cancer patients unfit for surgery and chemotherapy: a 10-year experience from the Norwegian Radium Hospital. Acta Oncol 2010; 49 (2): 209-18.
19. Wang Y, Shi XH, He SQ, et al. Comparison between con- tinuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2002; 54 (1): 131-6.
20. Zhao KL, Shi XH, Jiang GL, et al. Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma. Int J Radiat Oncol Biol Phys 2004; 60 (1): 123-9.
21. Arnott SJ, Duncan W, Gignoux M, et al.; Oeosphageal Cancer Collaborative Group. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; (4): CD001799.
22. Schlag P. Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus: CAO Esopha-geal Cancer Study Group [in German]. Chirurg 1992; 63 (9): 709-14.
23. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16 (6): 1104-9; discussion 1110.
24. Maipang T, Vasinanukorn P, Petpichetchian C, et al. In- duction chemotherapy in the treatment of patients with carcinoma ofthe esophagus. J Surg Oncol 1994; 56(3): 191-7. (Pubitemid 24226640)
25. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114 (2): 210-7.
26. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91 (11): 2165-74. (Pubitemid 32476382)
27. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359 (9319): 1727-33.
28. Allum WH, Stenning SP, Bancewicz J, et al. Long-term re- sults of a randomized trial of surgery with or without pre-operative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27 (30): 5062-7.
29. Kelsen DP, Winter KA, Gunderson LL, et al.; Radiation Therapy Oncology Group; USA Intergroup. Long-term results ofRTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25 (24): 3719-25. (Pubitemid 47372613)
30. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy fol- lowed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339 (27): 1979-84. (Pubitemid 29024130)
31. Cunningham D, Allum WH, Stenning SP, et al.; MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 (1): 11-20.
32. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial [abstract]. J Clin Oncol 2007; 25 (18S June 20 Suppl.): 4510.
33. Gebski V, Burmeister B, Smithers BM, et al.; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oeso-phageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8 (3): 226-34. (Pubitemid 46291702)
34. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastro-enterology 1994; 41 (4): 391-3. (Pubitemid 24273251)
35. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradio- therapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337 (3): 161-7. (Pubitemid 27306287)
36. Natsugoe S, Okumura H, Matsumoto M, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus 2006; 19 (6): 468-72. (Pubitemid 44644683)
37. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiother- apy, and surgery compared with surgery alone for esopha-geal cancer: CALGB 9781. J Clin Oncol 2008; 26(7): 1086-92.
38. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19 (2): 305-13. (Pubitemid 32112841)
39. Burmeister BH, Smithers BM, Gebski V, et al.; Trans- Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6 (9): 659-68. (Pubitemid 41222756)
40. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Ra- diation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20 (5): 1167-74. (Pubitemid 34177421)
41. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23 (10): 2310-7. (Pubitemid 46218723)
42. Bedenne L, Michel P, Bouche O, et al. Chemoradiation fol- lowed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25 (10): 1160-8. (Pubitemid 46640561)
43. Borghesi S, Hawkins MA, Tait D. Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol) 2008; 20 (3): 221-6.
44. Wales Cancer Trials Unit. Cisplatin, capecitabine, and ra- diation therapy with or without cetuximab in treating patients with esophageal cancer [clinicalTrials.gov identifier NCT00509561]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 2].
45. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114 (2): 205-9. (Pubitemid 27364210)
46. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 2003; 21 (24): 4592-6. (Pubitemid 46594032)
47. Teniere P, Hay JM, Fingerhut A, et al. Postoperative ra- diation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial: French University Association for Surgical Research. Surg Gynecol Obstet 1991; 173 (2): 123-30.
48. Fok M, Sham JS, Choy D, et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 113 (2): 138-47. (Pubitemid 23060521)
49. Zieren HU, Muller JM, Jacobi CA, et al. Adjuvant post- operative radiation therapy after curative resection of squa-mous cell carcinoma ofthe thoracic esophagus: a prospective randomized study. World J Surg 1995; 19 (3): 444-9.
50. Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 2003; 75 (2): 331-6. (Pubitemid 36184465)
51. Malthaner RA, Wong RK, Rumble RB, et al.; Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35.
52. Tachibana M, Yoshimura H, Kinugasa S, et al. Post- operative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol 2003; 29 (7): 580-7. (Pubitemid 37121758)
53. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347 (21): 1662-9. (Pubitemid 35340784)
54. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246 (6): 992-1000; discussion 1000-1. (Pubitemid 350179188)
55. Chang AC, Ji H, Birkmeyer NJ, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008; 85 (2): 424-9.
56. Biere SS, Cuesta MA, van der Peet DL. Minimally invasive versus open esophagectomy for cancer: a systematic review and meta-analysis. Minerva Chir 2009; 64 (2): 121-33.
57. Portale G, Hagen JA, Peters JH, et al. Modern 5-year sur- vival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 2006; 202 (4): 588-96; discussion 596-8.
58. Lerut T, Nafteux P, Moons J, et al. Three-field lympha- denectomy for carcinoma of the esophagus and gastro-esophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240 (6): 962-72; discussion 972-4.
59. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002; 236 (3): 376-84; discussion 384-5.
60. Macdonald JS, Benedetti J, Smalley S, et al. Chemoradia- tion of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008) [abstract no. 4515]. Int J Clin Oncol 2009; 27 Suppl.: 15s.
61. Medical Research Council Combination chemotherapy in treating patients with esophageal cancer [ClinicalTrials.gov identifier NCT00041262]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL http://clinicaltrials.gov [Accessed 2011 Mar 2].
62. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adeno-carcinoma [published erratum appears in N Engl J Med 1999 Jul 29; 341 (5): 384]. N Engl J Med 1996; 335 (7): 462-7.
63. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemo-radiotherapy in patients with locally advanced adenocarci-noma of the esophagogastric junction. J Clin Oncol 2009; 27 (6): 851-6.
64. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarci- nomas of the esophagogastric junction. J Clin Oncol 2006; 24 (29): 4692-8. (Pubitemid 46646244)
65. Lordick F, Ott K, Krause BJ, et al. PET to assess early me- tabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8 (9): 797-805. (Pubitemid 47308659)
66. Lordick F, Meyer Zum Bueschenfelde C, Herrmann K, et al. PET-guided treatment in locally advanced adeno-carcinoma of the esophagogastric junction (AEG): the MUNICON-II study. 2011 Gastrointestinal Cancers Symposium [abstract]. J Clin Oncol 2011; 29 Suppl. 4: 3.
67. Bamias A, Cunningham D, Nicolson V, et al. Adjuvant che- motherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study. Br J Cancer 1995; 71 (3): 583-6.
68. Armanios M, Xu R, Forastiere AA, et al. Adjuvant che- motherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group [published erratum appears in J Clin Oncol 2008 Aug 1; 26 (22): 3819]. J Clin Oncol 2004; 22 (22): 4495-9.
69. Macdonald JS, Smalley SR, Benedetti J, et al. Chemo- radiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345 (10): 725-30.
70. Cunningham D, Starling N, Rao S, et al.; Upper Gastro- intestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358 (1): 36-46.
71. Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitab-ine-based combination chemotherapy and infused 5-fluoro-uracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20 (9): 1529-34.
72. Bang YJ, Van Cutsem E, Feyereislova A, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published erratum appears in Lancet 2010 Oct 16; 376 (9749): 1302]. Lancet 2010; 376 (9742): 687-97.
73. Medical Research Council. Combination chemotherapy with or without bevacizumab in treating patients with previously untreated stomach cancer or gastroesophageal junction cancer that can be removed by surgery [ClinicalTrials.gov identifier NCT00450203]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 2]